FOR LABORATORY RESEARCH USE ONLY — not for human or veterinary use, diagnosis, treatment, or cosmetic application. Buyers must be 21+ and legally permitted to purchase research chemicals in their jurisdiction.Intended-use statement →
Cagrilintide Wholesale
Long-acting amylin analogue — dual-pathway metabolic research with GLP-1 complementarity
Product Identity
| CAS Number | 2489551-48-6 |
| Peptide Class | Amylin Analogue |
| Molecular Weight | ~4,543 Da |
| Structural Feature | C20 fatty diacid linker for albumin binding |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% by HPLC |
| Storage | 2–8°C, desiccated, protect from light |
Factory-directShenzhen, China
Available Configurations
| Configuration | Content | Best For |
|---|---|---|
| Standard Kit | 5 mg × 10 vials | Standard research configuration |
| Bulk Kit | 10 mg × 10 vials | Higher-dose single molecule |
| Cag/Sema Stack | Cagrilintide 5mg + Semaglutide 5mg × 10 | Dual-pathway fixed-dose combination |
| Custom | Custom mg × custom vials | OEM; private-label; protocol-specific |
Research Background
Cagrilintide is a long-acting acylated amylin analogue incorporating a C20 fatty diacid linker for albumin binding — the same pharmacokinetic strategy used in semaglutide. It targets the amylin pathway (AMY-R) via the area postrema, producing delayed gastric emptying, reduced postprandial glucagon, and central appetite modulation — distinct from and complementary to GLP-1 receptor agonism.
Proposed Mechanisms
Research Focus Areas
Slows nutrient delivery via AP → DVC pathway; extended duration with acylated format
Inhibits postprandial glucagon — complementary to GLP-1-mediated insulin secretion
Central signaling via area postrema neurons — distinct satiety circuit from GLP-1 pathways
Combined GLP-1 + amylin engagement for non-overlapping metabolic effects
Quality Specifications
| Parameter | Method | Criterion |
|---|---|---|
| Purity | RP-HPLC, C18 column, 220nm | ≥99.0% |
| Identity | ESI-MS | MW match within ±1 Da |
| Peptide Content | Amino Acid Analysis | 80–90% (net peptide) |
| Acylation Fidelity | LC-MS | Confirmed C20 diacid conjugation |
| Water Content | Karl Fischer | ≤8% |
| Appearance | Visual | White to off-white lyophilized powder |
Tiered Wholesale Pricing
| Kit size | Code | List price |
|---|---|---|
| 5 mg × 10 vials | CGL5 | US$109 |
| 10 mg × 10 vials | CGL10 | US$172 |
US$109–172 per kit (10 vials), from our published wholesale price list; tiered volume discounts apply (see the tier table) — source:wholesale price list (PDF, updated 2026-08-08).
| Volume | Discount | For |
|---|---|---|
| 1 kit | List price | Evaluation; competitive analysis |
| 5+ kits | 10% off | Initial portfolio expansion |
| 20+ kits | 20% off | Mid-size distributors |
| 50+ kits | 30% off | Regional distributors |
FAQ
How does Cagrilintide complement GLP-1 receptor agonists?
Cagrilintide targets the amylin pathway (AMY-R) via the area postrema, producing distinct effects: delayed gastric emptying, reduced postprandial glucagon, and central appetite modulation. GLP-1 agonists target GLP-1R in the hypothalamus and GI tract. Together, they engage two independent satiety and nutrient-processing pathways — this is the basis for dual-pathway research protocols.
What are the recommended storage conditions?
Store lyophilized powder at 2–8°C, protected from light and moisture. Under these conditions, stability is maintained for the shelf-life period indicated in the batch COA. Avoid repeated freeze-thaw cycles. After reconstitution, solution stability is protocol-dependent; validate within your laboratory's specific conditions.
Do you offer Cagrilintide in combination vials with GLP-1 peptides?
Yes. We manufacture custom fixed-dose combination kits — for example, Cagrilintide 5mg + Semaglutide 5mg in a single vial (SKU: PSH-CAGSEMA-5MG). Minimum order quantities apply for custom formulations. This pre-formulated stack simplifies laboratory workflows and ensures batch-to-batch consistency across both molecules.
How does Cagrilintide compare to other amylin analogues?
Cagrilintide is a long-acting acylated amylin analogue engineered for extended half-life via C20 fatty acid conjugation. Compared to native amylin (t½ ~13 min) or pramlintide (t½ ~50 min), Cagrilintide's structural modifications confer significantly longer residence time, enabling once-weekly dosing in research protocols.
All products are manufactured for laboratory research purposes only. Cagrilintide is labeled FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, diagnosis, treatment, prophylaxis or any clinical, cosmetic, dietary or household application. Not a dietary supplement, pharmaceutical ingredient, cosmetic ingredient or approved drug substance. Buyers are responsible for verifying the legal status of importation and possession in their destination country. Amylin analogues are prescription or investigational substances in many jurisdictions — buyers must confirm the legal status of importation and possession, and hold any required authorisation.
Ready to Add Cagrilintide to Your Portfolio?
Bulk pricing, COA, and dual-pathway stack configurations available. Contact Dr. Aaron Wang directly.